ClinicalTrials.gg
TerminatedNCT02703272Updated Dec 2, 2022Results posted

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

A Phase 3 interventional study of Ibrutinib and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Janssen Research & Development, LLC. Terminated at 77 sites in 20 countries. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2022-12-02.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. ibrutinib · Lymphoma, Non-Hodgkin.

Enrollment
9th of 18
72 · median 72
Started
2016
with 1 other
Phase 3
4 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
2 of 18
Janssen Research & Development, LLC

Among the 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 9th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).

Read the detailed description

This is a Phase 3, randomized (study medication assigned to participants by chance), open-label (identity of study drug will be known to participant and study staff), controlled study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in part, which will be conducted before starting the randomized part (Part 2) of the study and Part 2 is a randomized and open-label study. Part 1 and Part 2 of the study will be conducted in 3 phases: a Pretreatment (Screening) Phase (Up to 14 days before administration of study drug), a Treatment Phase, and a Posttreatment Phase. The Treatment Phase will extend from enrollment (in Part 1) or randomization (in Part 2) until 1 of the following: 1) completion of 3 cycles of therapy, 2) transplantation, if clinically indicated, or 3) progressive disease (PD), whichever comes first. The Posttreatment Phase will continue until death, loss to follow up, consent withdrawal, or study end, whichever occurs first. The end of study is defined as when approximately 60 event-free survival (EFS) events have occurred in Part 2 (death, disease progression, or lack of complete response [CR] or partial response [PR] after 3 cycles of treatment based on blinded independent event review), or the sponsor terminates the study, whichever comes first. Participants in Part 1 will be 1 to less than (\<) 18 years old. Participants in Part 2 will be 1 to 30 years old. Participants will be primarily evaluated for pharmacokinetics in part 1 and efficacy (EFS) of ibrutinib in combination with RICE or RVICI background therapy compared to RICE or RVICI background therapy alone in part 2. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Lymphoma, Non-Hodgkin
  • Ibrutinib
  • JNJ-54179060
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with 1 to less than (\<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at \<18 years of age (Part 2 only)
  • Participants must be in first recurrence and have received only one or have disease that is primarily to conventional therapy
  • Participants must have at least 1 of the following: 1 site of greater than (>) 1 centimeter (cm) in the longest diameter and >1 cm in the shortest diameter by radiological imaging; bone marrow involvement; cerebrospinal fluid with blasts present
  • Participants with lansky- score of greater than or equal to (>=) 50
  • Adolescent women/young women of must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study

Exclusion criteria

Exclusion Criteria:

  • Participants with ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known to be strong /5 inhibitors, or has taken any disallowed therapies as noted in Section 8.2, Prohibited Medications, before the planned first dose of study drug
  • Participants with inherited or acquired bleeding disorders
  • Participants with arrhythmias, complex congenital heart disease, or (LVEF) \<50 percent (%) or shortening fraction (SF) \<=28%
  • Participants with known history of (HIV) or active or C virus
  • Participants with any condition that could interfere with the absorption or metabolism of ibrutinib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
  • Participants with known allergies, , or intolerance to ibrutinib or its (refer to Investigator's Brochure)
  • A diagnosis of post-transplant lymphoproliferative disease (PTLD)
  • Participants who are within 6 months of an bone marrow transplant
  • Participants who have had prior exposure to ibrutinib
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part 1: Ibrutinib

    The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m\^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m\^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.

    Drug: Ibrutinib · Drug: Rituximab · Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Vincristine · Drug: Idarubicin · Drug: Dexamethasone

  • Experimental
    Part 2: Ibrutinib

    Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.

    Drug: Ibrutinib · Drug: Rituximab · Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Vincristine · Drug: Idarubicin · Drug: Dexamethasone

Interventions

  • Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.

  • Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.

  • Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

  • Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

  • Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.

  • Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.

  • Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.

  • Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

    AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square \[mg/m\^2\], 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  2. Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

    CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  3. Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

    Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  4. Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

    Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  5. Part 1: Relationship Between AUC and Body Size

    The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling.

    Time frame: Up to Cycle 3 (each cycle of 28 days)

  6. Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups

    EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the Independent Review Committee (IRC). CR was defined as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions, resected residual mass that was pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50 percent (%) decrease in sum of the products of the lesion diameters (SPD) on CT or MRI; fluorodeoxyglucose (FDG)-positron emission tomography (PET) may be positive, no new or progressive disease (PD); morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months)

Secondary outcomes

  1. Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to 4 year and 4 months

  2. Part 1 and Part 2: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants achieving a best overall response of either complete response (CR) (including CR biopsy-negative \[CRb\] and unconfirmed CR \[CRu\]) or partial response (PR) as evaluated by International Pediatric non-Hodgkin lymphoma (NHL) response criteria. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; bone marrow (BM) and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: Up to 4 year and 4 months

  3. Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline

    Tumor formalin-fixed paraffin-embedded (FFPE) samples were taken to evaluate the baseline gene expression by disease-specific biomarkers such as BCL-2L1 (BCL-xl), BIRC2 (cIAP1), Caspase 3 (CASP3), STAT3, and SYK. Transcripts per million (TPM) is a normalization method for RNA-sequencing, which means "for every 1,000,000 RNA molecules in the RNA-sequencing tumor FFPE sample, x came from this gene/transcript.

    Time frame: Baseline

  4. Part 1 and Part 2: Number of Participants With Immunoglobulin and T-cell Receptor Gene Rearrangements

    Number of participants with immunoglobulin and T-cell receptor gene rearrangements were reported.

    Time frame: At baseline (Cycle 1 Day 1) of Part 1 and 2

  5. Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy

    Number of participants with \>90% BTK occupancy were reported. Blood samples were collected to assess BTK occupancy.

    Time frame: Up to 3 months

  6. Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability

    Palatability of ibrutinib was measured by using a VAS. The scale is a 5-point visual analog scale incorporating a facial hedonic scale designed to span pediatric ages and levels of participant comprehension with a score range of 1 to 5, where 1 represents best score and 5 is worst palatability.

    Time frame: Day 1 of Cycle 1 and Cycle 3

  7. Part 1: Number of Participants With CD79B, CARD11, and MYD Mutations

    Number of Participants with CD79B, CARD11, and MYD Mutations were reported.

    Time frame: Up to 4 years and 4 months

  8. Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations

    Number of participants with CD79B, CARD11, and MYD mutations were reported. Blood samples were taken to evaluate the levels of biomarkers such as CD79B, CARD11, and MYD mutations.

    Time frame: Up to 4 year and 4 months

  9. Part 1: Number of Participants With c-MYC Gene Rearrangement

    Number of participants with c-MYC gene rearrangement were reported.

    Time frame: At baseline (Cycle 1 Day 1)

  10. Part 2: Number of Participants With c-MYC Gene Rearrangement

    Number of participants with c-MYC gene rearrangement were reported. Blood samples were taken to evaluate the levels of biomarker such as c-MYC Gene rearrangement.

    Time frame: At baseline (Cycle 1 Day 1)

  11. Part 2: Percentage of Participants Who Achieved Complete Response (CR)

    Complete response rate was defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment.

    Time frame: Up to 4 year and 4 months

  12. Part 2: Percentage of Participants Who Achieved Partial Response (PR)

    Percentage of participants who achieved PR were assessed. PR was defined as 50% decrease in SPD on computed tomography (CT) or magnetic resonance imaging (MRI); FDG-PET may be positive; no new or PD; morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: Up to 4 year and 4 months

  13. Part 2: Tumor Volume Reduction Rate at Day 14

    The tumor volume reduction rate was defined as percent decrease in the sum of the products of the lesion diameters at Day 14. It was measured as the mean change in the sum of the products of the lesion diameters (SPD) at Day 14.

    Time frame: At Day 14

  14. Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation

    Number of participants who proceeded to stem cell transplantation were reported.

    Time frame: Up to end of the study (Up to 4 year and 4 months)

  15. Part 2: Time to Response

    Time to response was defined as the time interval from the first dose of ibrutinib to the first documented response for those participants who responded. Time to response was summarized for participants who achieved either CR (including CRb and CRu) or PR. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: Up to 4 Years and 4 months

  16. Part 2: Duration of Response

    Duration of response was defined as the duration from date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death, whichever occurred first. PD: \>25% increase in SPD of residual lesions (calculated from nadir) on CT or MRI; Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline; documentation of new lesions or development of new morphologic evidence of disease in BM or CSF.

    Time frame: Up to 4 year and 4 months

  17. Part 2: Percentage of Participants With EFS at 2 Years

    EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: At 2 years

  18. Part 2: Percentage of Participants With EFS at 3 Years

    EFS is the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurs first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

    Time frame: At 3 years

  19. Part 2: Overall Survival

    Overall survival was defined as duration from the date of randomization to the date of the participant's death.

    Time frame: Up to 4 year and 4 months

  20. Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

    AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  21. Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

    CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  22. Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

    Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  23. Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

    Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

    Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)

  24. Part 2: Relationship Between AUC and Body Size

    The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling. This outcome measure was planned to be analyzed for specified arm only.

    Time frame: Up to Cycle 3 (each cycle of 28 days)

07

Results

Posted Dec 2, 2022

Participant flow

Participant flow — Overall Study
MilestonePart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Started11103516
Completed0000
Not completed11103516
Withdrew: Death491910
Withdrew: Withdrawal by subject0042
Withdrew: Study terminated by sponsor61124
Withdrew: Other1000

Outcome measures

PrimaryPart 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square \[mg/m\^2\], 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · hours*nanogram per milliliter (h*ng/mL)
Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
hours*nanogram per milliliter (h*ng/mL)Part 1: Ibrutinib: 240 mg/m^2Part 1: Ibrutinib: 329 mg/m^2Part 1: Ibrutinib: 440 mg/m^2
1-5 years143 (116 to 170)386 (386 to 386)310 (230 to 543)
6-11 years145 (140 to 233)349 (238 to 562)324 (185 to 538)
12-17 years1210 (939 to 1450)661 (394 to 778)—
PrimaryPart 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · milliliter per hour (mL/h)
Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
milliliter per hour (mL/h)Part 1: Ibrutinib: 240 mg/m^2Part 1: Ibrutinib: 329 mg/m^2Part 1: Ibrutinib: 440 mg/m^2
1-5 years1220 (1000 to 1430)508 (508 to 508)1200 (838 to 1550)
6-11 years1450 (1080 to 1500)805 (664 to 1100)1300 (910 to 2460)
12-17 years348 (340 to 433)729 (568 to 1330)—
PrimaryPart 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · liter(s)
Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
liter(s)Part 1: Ibrutinib: 240 mg/m^2Part 1: Ibrutinib: 329 mg/m^2Part 1: Ibrutinib: 440 mg/m^2
1-5 years11.1 (8.26 to 13.9)5.18 (5.18 to 5.18)7.63 (5.34 to 11.1)
6-11 years18 (10.8 to 29.9)7.55 (2.89 to 15.6)19 (6.09 to 55.9)
12-17 years3.63 (2.32 to 4.77)11.3 (6.34 to 18.5)—
PrimaryPart 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · nanograms per milliliter (ng/mL)
Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
nanograms per milliliter (ng/mL)Part 1: Ibrutinib: 240 mg/m^2Part 1: Ibrutinib: 329 mg/m^2Part 1: Ibrutinib: 440 mg/m^2
1-5 years3.86 (3.75 to 3.98)4.48 (4.48 to 4.48)5.07 (4.5 to 5.14)
6-11 years3.46 (3.12 to 3.6)3.64 (3.32 to 4.59)3.88 (3.2 to 4.44)
12-17 years4.88 (4.76 to 5.4)4.73 (4.07 to 5.07)—
PrimaryPart 1: Relationship Between AUC and Body Size

The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling.

Time frame:
Up to Cycle 3 (each cycle of 28 days)

No measurements were reported for this outcome.

PrimaryPart 2: Event Free Survival (EFS) Between the 2 Treatment Groups

EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the Independent Review Committee (IRC). CR was defined as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions, resected residual mass that was pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50 percent (%) decrease in sum of the products of the lesion diameters (SPD) on CT or MRI; fluorodeoxyglucose (FDG)-positron emission tomography (PET) may be positive, no new or progressive disease (PD); morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months)
Reported as:
Median · Months
Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups
MonthsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups6.05 (2.99 to 8.84)6.97 (2.60 to 11.07)
SecondaryPart 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability

An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Time frame:
Up to 4 year and 4 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability
ParticipantsPart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability11103515
SecondaryPart 1 and Part 2: Overall Response Rate (ORR)

ORR was defined as the percentage of participants achieving a best overall response of either complete response (CR) (including CR biopsy-negative \[CRb\] and unconfirmed CR \[CRu\]) or partial response (PR) as evaluated by International Pediatric non-Hodgkin lymphoma (NHL) response criteria. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; bone marrow (BM) and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
Up to 4 year and 4 months
Reported as:
Number · Percentage of participants
Part 1 and Part 2: Overall Response Rate (ORR)
Percentage of participantsPart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 1 and Part 2: Overall Response Rate (ORR)81.850.068.681.3
SecondaryPart 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline

Tumor formalin-fixed paraffin-embedded (FFPE) samples were taken to evaluate the baseline gene expression by disease-specific biomarkers such as BCL-2L1 (BCL-xl), BIRC2 (cIAP1), Caspase 3 (CASP3), STAT3, and SYK. Transcripts per million (TPM) is a normalization method for RNA-sequencing, which means "for every 1,000,000 RNA molecules in the RNA-sequencing tumor FFPE sample, x came from this gene/transcript.

Time frame:
Baseline
Reported as:
Mean · Transcripts per million
Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline
Transcripts per millionPart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
BCL-2L1 (BCL-xl)——58.09346 ± 38.7599674.30790 ± 75.82331
BIRC2 (cIAP1)——47.20787 ± 16.2643040.01716 ± 9.28104
Caspase 3 (CASP3)——51.14711 ± 21.4410947.61412 ± 32.12666
STAT3——540.02256 ± 363.75256526.35308 ± 473.08255
SYK——705.29909 ± 503.07085618.36324 ± 144.72067
SecondaryPart 1 and Part 2: Number of Participants With Immunoglobulin and T-cell Receptor Gene Rearrangements

Number of participants with immunoglobulin and T-cell receptor gene rearrangements were reported.

Time frame:
At baseline (Cycle 1 Day 1) of Part 1 and 2

No measurements were reported for this outcome.

SecondaryPart 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy

Number of participants with \>90% BTK occupancy were reported. Blood samples were collected to assess BTK occupancy.

Time frame:
Up to 3 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy
ParticipantsPart 1: IbrutinibPart 2: Ibrutinib
Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy55
SecondaryPart 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability

Palatability of ibrutinib was measured by using a VAS. The scale is a 5-point visual analog scale incorporating a facial hedonic scale designed to span pediatric ages and levels of participant comprehension with a score range of 1 to 5, where 1 represents best score and 5 is worst palatability.

Time frame:
Day 1 of Cycle 1 and Cycle 3
Reported as:
Mean · Units on a scale
Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability
Units on a scalePart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)
Cycle 1 Day 12.6 ± 1.213.2 ± 1.402.4 ± 1.16
Cycle 3 Day 13.3 ± 1.392.3 ± 1.152.6 ± 0.89
SecondaryPart 1: Number of Participants With CD79B, CARD11, and MYD Mutations

Number of Participants with CD79B, CARD11, and MYD Mutations were reported.

Time frame:
Up to 4 years and 4 months

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With CD79B, CARD11, and MYD Mutations

Number of participants with CD79B, CARD11, and MYD mutations were reported. Blood samples were taken to evaluate the levels of biomarkers such as CD79B, CARD11, and MYD mutations.

Time frame:
Up to 4 year and 4 months
Reported as:
Count of participants · Participants
Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations
ParticipantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
CD79B10
CARD1110
MYD mutation00
SecondaryPart 1: Number of Participants With c-MYC Gene Rearrangement

Number of participants with c-MYC gene rearrangement were reported.

Time frame:
At baseline (Cycle 1 Day 1)

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With c-MYC Gene Rearrangement

Number of participants with c-MYC gene rearrangement were reported. Blood samples were taken to evaluate the levels of biomarker such as c-MYC Gene rearrangement.

Time frame:
At baseline (Cycle 1 Day 1)
Reported as:
Count of participants · Participants
Part 2: Number of Participants With c-MYC Gene Rearrangement
ParticipantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Number of Participants With c-MYC Gene Rearrangement11
SecondaryPart 2: Percentage of Participants Who Achieved Complete Response (CR)

Complete response rate was defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment.

Time frame:
Up to 4 year and 4 months
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants Who Achieved Complete Response (CR)
Percentage of ParticipantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Percentage of Participants Who Achieved Complete Response (CR)17.118.8
SecondaryPart 2: Percentage of Participants Who Achieved Partial Response (PR)

Percentage of participants who achieved PR were assessed. PR was defined as 50% decrease in SPD on computed tomography (CT) or magnetic resonance imaging (MRI); FDG-PET may be positive; no new or PD; morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
Up to 4 year and 4 months
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Achieved Partial Response (PR)
percentage of participantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Percentage of Participants Who Achieved Partial Response (PR)51.462.5
SecondaryPart 2: Tumor Volume Reduction Rate at Day 14

The tumor volume reduction rate was defined as percent decrease in the sum of the products of the lesion diameters at Day 14. It was measured as the mean change in the sum of the products of the lesion diameters (SPD) at Day 14.

Time frame:
At Day 14
Reported as:
Least squares mean · Percent change
Part 2: Tumor Volume Reduction Rate at Day 14
Percent changePart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Tumor Volume Reduction Rate at Day 14-49.7 ± 33.41-58.60 ± 34.04
SecondaryPart 2: Number of Participants Who Proceeded to Stem Cell Transplantation

Number of participants who proceeded to stem cell transplantation were reported.

Time frame:
Up to end of the study (Up to 4 year and 4 months)
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
ParticipantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation137
SecondaryPart 2: Time to Response

Time to response was defined as the time interval from the first dose of ibrutinib to the first documented response for those participants who responded. Time to response was summarized for participants who achieved either CR (including CRb and CRu) or PR. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
Up to 4 Years and 4 months
Reported as:
Median · Months
Part 2: Time to Response
MonthsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Time to Response0.89 (0.49 to 1.87)0.82 (0.46 to 1.94)
SecondaryPart 2: Duration of Response

Duration of response was defined as the duration from date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death, whichever occurred first. PD: \>25% increase in SPD of residual lesions (calculated from nadir) on CT or MRI; Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline; documentation of new lesions or development of new morphologic evidence of disease in BM or CSF.

Time frame:
Up to 4 year and 4 months
Reported as:
Median · Months
Part 2: Duration of Response
MonthsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Duration of Response6.01 (3.06 to NA)6.51 (4.53 to 10.64)
SecondaryPart 2: Percentage of Participants With EFS at 2 Years

EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
At 2 years
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants With EFS at 2 Years
Percentage of participantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Percentage of Participants With EFS at 2 Years14.312.5
SecondaryPart 2: Percentage of Participants With EFS at 3 Years

EFS is the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurs first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.

Time frame:
At 3 years
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants With EFS at 3 Years
Percentage of participantsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Percentage of Participants With EFS at 3 Years8.612.5
SecondaryPart 2: Overall Survival

Overall survival was defined as duration from the date of randomization to the date of the participant's death.

Time frame:
Up to 4 year and 4 months
Reported as:
Median · Months
Part 2: Overall Survival
MonthsPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Part 2: Overall Survival14.13 (5.98 to NA)11.07 (7.39 to NA)
SecondaryPart 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Mean · h*ng/mL
Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
h*ng/mLPart 2: Ibrutinib: 240 mg/m^2:Part 2: Ibrutinib: 329 mg/m^2Part 2: Ibrutinib: 440 mg/m^2
1-5 years——298 (268 to 327)
6-11 years——655 (428 to 879)
12-17 years215 (215 to 215)499 (262 to 887)—
18+ years—423 (348 to 498)—
SecondaryPart 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · mL/h
Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
mL/hPart 2: Ibrutinib: 240 mg/m^2Part 2: Ibrutinib: 329 mg/m^2Part 2: Ibrutinib: 440 mg/m^2
1-5 years——1110 (1020 to 1200)
6-11 years——856 (618 to 1140)
12-17 years1730 (1730 to 1730)982 (598 to 2010)—
18+ years—1510 (1250 to 1780)—
SecondaryPart 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · liter(s)
Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
liter(s)Part 2: Ibrutinib: 240 mg/m^2Part 2: Ibrutinib: 329 mg/m^2Part 2: Ibrutinib: 440 mg/m^2
1-5 years——1.68 (1.46 to 1.91)
6-11 years——6.18 (3.67 to 10.01)
12-17 years9.9 (9.9 to 9.9)4.14 (1.46 to 8.51)—
18+ years—9.29 (7.75 to 10.8)—
SecondaryPart 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.

Time frame:
Up to Cycle 3 (each cycle of 21 or 28 days)
Reported as:
Median · ng/mL
Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
ng/mLPart 2: Ibrutinib: 240 mg/m^2Part 2: Ibrutinib: 329 mg/m^2Part 2: Ibrutinib: 440 mg/m^2
1-5 years——3.79 (3.52 to 4.06)
6-11 years——4.15 (3.44 to 5.01)
12-17 years2.93 (2.93 to 2.93)4.86 (3.12 to 5.26)—
18+ years—3.7 (3.46 to 3.94)—
SecondaryPart 2: Relationship Between AUC and Body Size

The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling. This outcome measure was planned to be analyzed for specified arm only.

Time frame:
Up to Cycle 3 (each cycle of 28 days)

No measurements were reported for this outcome.

Adverse events

Collected over Up to 4 year and 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Ibrutinib+RICE4/11 (36.4%)10/11 (90.9%)11/11 (100%)
Part 1: Ibrutinib+RVICI9/10 (90%)9/10 (90%)10/10 (100%)
Part 2: Ibrutinib+CIT (RICE or RVICI)19/35 (54.3%)25/35 (71.4%)35/35 (100%)
Part 2: Chemoimmunotherapy10/15 (66.7%)11/15 (73.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventPart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
Febrile NeutropeniaBlood and lymphatic system disorders4/113/1021/356/15
SepsisInfections and infestations1/114/105/353/15
ThrombocytopeniaBlood and lymphatic system disorders0/110/103/354/15
AnaemiaBlood and lymphatic system disorders0/110/102/353/15
LeukopeniaBlood and lymphatic system disorders0/110/100/353/15
NeutropeniaBlood and lymphatic system disorders2/111/102/353/15
Escherichia SepsisInfections and infestations0/110/101/352/15
Sinus TachycardiaCardiac disorders0/111/100/350/15
ColitisGastrointestinal disorders0/111/101/351/15
DiarrhoeaGastrointestinal disorders0/111/100/350/15
Most frequent other events
Showing 10 of 202
Most frequent other events
EventPart 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: Chemoimmunotherapy
AnaemiaBlood and lymphatic system disorders8/119/1029/3514/15
ThrombocytopeniaBlood and lymphatic system disorders6/118/1019/354/15
VomitingGastrointestinal disorders5/115/1025/354/15
NauseaGastrointestinal disorders7/115/1021/352/15
NeutropeniaBlood and lymphatic system disorders6/116/1014/354/15
DiarrhoeaGastrointestinal disorders4/116/1010/353/15
Neutrophil Count DecreasedInvestigations1/112/1012/359/15
HypokalaemiaMetabolism and nutrition disorders2/116/1012/356/15
Platelet Count DecreasedInvestigations5/112/1012/358/15
Abdominal PainGastrointestinal disorders3/115/1012/352/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: ChemoimmunotherapyTotal
Mean10.5 ± 4.918.3 ± 3.4313.9 ± 3.9413.2 ± 4.3712.4 ± 4.54
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: ChemoimmunotherapyTotal
Female3112319
Male89231353
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: ChemoimmunotherapyTotal
American Indian or Alaska Native00000
Asian108615
Black or African American00011
Native Hawaiian or Other Pacific Islander00000
White91022849
More than one race00000
Unknown or Not Reported10304
Other00213
Region of Enrollment
Region of Enrollment(Participants)Part 1: Ibrutinib+RICEPart 1: Ibrutinib+RVICIPart 2: Ibrutinib+CIT (RICE or RVICI)Part 2: ChemoimmunotherapyTotal
BELGIUM00202
BRAZIL10124
BULGARIA00202
CANADA00101
CZECH REPUBLIC02204
FRANCE21317
GERMANY21306
ITALY21429
NETHERLANDS00112
POLAND01023
ROMANIA10001
RUSSIAN FEDERATION00202
SOUTH KOREA105410
SPAIN00202
SWEDEN00101
TAIWAN00213
TURKEY14128
UKRAINE00101
UNITED KINGDOM00112
UNITED STATES10102
08

Study locations

77 sites
  • Los Angeles, California, United States
  • Orange, California, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia, United States
  • Atlanta, Georgia, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • New York, New York, United States
  • Valhalla, New York, United States
  • Charlotte, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
  • Milwaukee, Wisconsin, United States
  • Brussel, Belgium
  • Leuven, Belgium
  • Barretos, Brazil
  • Curitiba, Brazil
  • Sao Paulo, Brazil
  • São Paulo, Brazil
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Halifax, Nova Scotia, Canada
  • Toronto, Ontario, Canada
  • Brno, Czechia
  • Praha, Czechia
  • Bordeaux, France
  • Lille, France
  • Lyon, France
  • Marseille, France
  • Nantes, France
  • Toulouse, France
  • Vandoeuvre les Nancy, France
  • Villejuif, France
  • Berlin, Germany
  • Freiburg, Germany
  • Kiel, Germany
  • München, Germany
  • Münster, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Seoul, Korea, Republic of
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Krakow, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Oradea, Romania
  • Timisoara, Romania
  • Ekaterinburg, Russian Federation
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
  • Barcelona, Spain
  • Esplugues de Llobregat, Spain
  • Madrid, Spain
  • Valencia, Spain
  • Gothenburg, Sweden
  • Kaohsiung, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
  • Ankara, Turkey
  • Izmir, Turkey
  • Kiev, Ukraine
  • Birmingham, United Kingdom
  • Cambridge, United Kingdom
  • Leeds, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Newcastle, United Kingdom
  • Sheffield, United Kingdom
  • Surrey, United Kingdom
09

References and documents

Publications

  • Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology. 2018 Oct 11;8(1):e1512455. doi: 10.1080/2162402X.2018.1512455. eCollection 2019. PubMed 30546948 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Jun 2021, 59 months.

Results were first posted in Dec 2022, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2016
First posted
Mar 9, 2016
StartActual
Jul 1, 2016
Primary completionActual
Jun 11, 2021
CompletionActual
Jun 11, 2021
Results first posted
Dec 2, 2022
Last update
Dec 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02703272
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 9, 2016
Start date
Jul 1, 2016
Primary completion
Jun 11, 2021
Completion
Jun 11, 2021
Results posted
Dec 2, 2022
Last update
Dec 2, 2022

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion